9 "Lung" clinical trials found.
-
A Phase 1/2a Open-Label Multi-Center Trial to Assess Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of CLN-081 in Patients With Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
The purpose of the study is to look at safety and tolerability of orally administered CLN-081 monotherapy, as single dose and after multiple doses over ...Phase
Interventional
-
A Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Patients with Advanced NSCLC and Other Solid Tumors (ALKOVE-1)
This study is designed for patients diagnosed with advanced NSCLC and other solid tumors with an ALK mutation. (NYU-Nuvalent NVL-655)
Phase
Interventional
-
A Modular Open-label Phase I/II Study to Evaluate the Safety Tolerability Pharmacokinetics and Efficacy of EP0031 in Patients with Advanced RET-altered Malignancies
RET alterations mostly happen in lung cancer and thyroid cancer, these alterations can be picked up on molecular testing and can be a target for ...
Phase
Interventional
-
EVEREST-1: A Phase 1/2 Study to Evaluate the Safety and Efficacy of A2B530 an Autologous Logic-gated Tmod Chimeric Antigen Receptor T Cell (CAR T) in Heterozygous HLA-A*02 Adult Subjects with Recurrent Unresectable Locally Advanced or Metastatic Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression
This is a study to see if a new treatment called A2B530 is safe and effective for people with certain types of cancer that have ...
Phase
Interventional
-
Phase 1/2 Multi-Center Open-Label Study to Evaluate the Safety Tolerability and Preliminary Anti-tumor Activity of TNG462 in Patients with MTAP-deleted Advanced or Metastatic Solid Tumors
A study called TNG462-C101 is being conducted to test a new medicine called TNG462 on patients with advanced or metastatic solid tumors who have a ...
Phase
Interventional
-
A Phase 1/2 Open-Label Study to Evaluate the Safety Tolerability Pharmacokinetics and Efficacy of TNG260 as Single Agent and in Combination with an anti-PD-1 Antibody in Patients with STK11-Mutated Advanced Solid Tumors
This study is testing a new drug called TNG260 (a specific medicine referred to as a CoreDAC inhibitor that can undo the way the immune ...
Phase
Interventional
-
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation
The purpose of this study is to test the safety, tolerability, and effectiveness of MRTX849 (called “the study drug” from now on) for advanced cancers ...Phase
Interventional
-
A Phase 1/2 Open-Label Multi-Center First-in-Human Study of the Safety Tolerability Pharmacokinetics and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK ROS1 or NTRK1-3 Rearrangements (TRIDENT-1)
The purpose of this Phase 1/2 research study is to test the effects of an investigational study drug called repotrectinib for the possible treatment ...Phase
Interventional
-
A Phase 1/2 First-in-Human Study of DCC-3116 as Monotherapy and in Combination with RAS/MAPK Pathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations
This study is designed for patients who have Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway MutationsThe objective of the study is to ...
Phase
Interventional
